IFN-α2b has been often used in immunotherapy for various cancer patients and its concentrations up to 5 × 106 IU have been shown to be relatively safe and tolerable in those with prostate cancer [9,22]. The gene discussed is IFNA2; the disease is prostate carcinoma.